Graison Dangor Contributor Healthcare I cover the intersection of mental health, the economy, and policy. A tool that helps pediatricians diagnose autism with artificial intelligence and smartphone video passed a key FDA test and could hit the market as soon as next summer, according to device-maker Cognoa, which recently announced its plans to submit the tool for final approval. In…
By Meg Bryant Children with autism spectrum disorder (ASD) can face a lifetime of frustration because of challenges with communication, social behaviors and flexibility of thought. Early intervention can improve outcomes, but nailing a diagnosis of ASD often takes years. Cognoa Inc. wants to change that with its digital ASD Diagnostic and is on track to apply for U.S. FDA clearance before the…
by Conor Hale Cognoa aims to equip primary care pediatricians with an artificial-intelligence-powered digital app that can spot the signs of autism, allowing them to rule out or diagnose spectrum disorders within the doctor’s office or remotely. This could represent a broad shift in the standard of care, as most children are referred to specialists for diagnosis and later treatment—a process…
The startup Cognoa has submitted its app-based tool for FDA clearance By Megan Scudellari This week, a California-based company announced it will seek FDA clearance for a first-of-its-kind autism spectrum disorder (ASD) diagnostic tool. Cognoa’s technology uses artificial intelligence to make an ASD diagnosis within weeks of signs of concern—far faster than the current standard of care. If cleared by the FDA, it would be…
Cognoa’s autism diagnostic device is positioned to be the first FDA-cleared digital solution enabling pediatricians to diagnose autism – a paradigm shift in the standard of care (Palo Alto, Calif. – September 23, 2020) – Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, announced today that…
by Elaine Roth There was no preparation for the transition into lockdown. One day, COVID-19 was a vague virus I was reading about in the news, and the next, it was here—in my small town, in my schools. And everything shut down with alarming speed. The change to stay-at-home life happened almost literally overnight for my kids. We had no time to plan. The…
Researchers and advocates have convincingly shown that the wide gap in diagnoses between boys and girls isn’t simply a matter of boys being significantly more likely to be on the autism spectrum. By DAVID HAPPEL Statistically, boys are four times as likely as girls to receive a diagnosis of autism spectrum disorder (ASD). But that’s not because boys are four times as likely to have ASD. According…
Happel takes up the top job at Cognoa after over 25 years of successfully commercializing medical products and as a leader in the biotech and biopharma industries. (Palo Alto, Calif. – March 24, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today the appointment of David Happel as Chief Executive Officer. Cognoa’s former CEO…
An Interview with Cognoa’s CEO Brent Vaughan In the US, one in five children are living with a diagnosable behavioral health disorder; however, only 21% of those children who are diagnosed receive needed treatment. Often, parents have to wait one to three years to receive a proper and accurate diagnosis, and an individualized treatment plan for their child. For the last 15 years, the average…
Ronit Molko, Ph.D., BCBA-D describes how AI will become the norm of autism services, as it has in other industries, including Cognoa’s digital therapeutics that create a more proactive role for parents and pediatricians in the diagnostic and treatment processes to accomplish early intervention. Read full article here.
